EGFR and non-small cell lung carcinoma: Previous studies reported by our group demonstrated that acquired epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant EGFR-mutant NSCLC cells not only overexpressed AXL, but also demonstrated a concomitant EMT-associated transcriptional program involving upregulation of vimentin (Zhang et al. 2012).